What is Humacyte's gross profit margin?

What guidance did Humacyte's management provide for the next earnings period?

What were the key takeaways from Humacyte’s earnings call?

What is the market's earnings forecast for Humacyte next quarter?

What is the revenue and EPS growth rate for Humacyte year over year?

What does Humacyte do and what are its main business segments?

Did Humacyte beat or miss consensus estimates last quarter?

What is Humacyte's latest dividend and current dividend yield?

- **Symvess Commercial Breakthrough**: 92 hospitals approved, Q3 sales surge to $703K, with first military sale.
- **Clinical Excellence**: 92% patency in complex cases, comparable to autologous vein, and 87% potency in combat injuries.
- **Financial Resilience**: $76.3M cash runway, 24% R&D reduction, and $50M+ cost savings on track.
- **Strategic Focus**: Dialysis BLA submission in 2026, coronary trial in 2026, and no NTAP resubmission.

**【CEO Summary Section】**
- **Commercial Momentum**: 25 hospitals (representing 92 civilian facilities) approved Symvess, with Q3 sales of $703,000, up from $100,000 in Q2. First military sale achieved via ECAT listing.
- **Clinical Validation**: Publications show 92% secondary patency in iatrogenic injuries, 87.1% potency in Ukraine combat patients, and comparable outcomes to autologous vein in trauma.
- **Pipeline Progress**: Dialysis access trial (V007) shows 2-year durability in high-risk patients; interim analysis of V012 (women-focused) expected in April 2026. Coronary vessel preclinical success; IND filed for 2026 CABG trial.

**【CFO Financial Commentary】**
- **Revenue**: Q3 2025: $0.8M (Symvess: $0.7M); 9M 2025: $1.6M (Symvess: $0.9M).
- **Expenses**: R&D: $17.3M (down 24% YoY); SG&A: $7.6M (up 5% YoY). COGS: $0.3M.
- **Net Loss**: $17.5M (vs. $39.2M YoY); cash: $19.8M + $56.5M post-quarter, runway >12 months.

**【Q&A Key Highlights】**
- **Reorder Activity**: Majority of initial-order hospitals have reordered.
- **Cost Savings**: R&D down $5M QoQ; $50M+ savings target on track.
- **NTAP Strategy**: No resubmission due to CMS ruling; focus on commercial launch (4% Medicare coverage in trauma).
- **Dialysis BLA**: Submission in H2 2026 contingent on V012 interim results.
- **Real-World Data**: Post-approval registry to launch H1 2026, with early data expected 2027.

Humacyte, Inc. (HUMA) Q3 2025 Earnings Call Transcript

- **Commercial Breakthrough**: 82 hospitals now eligible for Symvess, with first military sale and $0.3M July revenue.
- **Strategic Pricing**: $24,250 price cut accelerates approvals, maintaining margins.
- **Pipeline Momentum**: ATEV trial shows superior outcomes in high-risk patients; IND filing for coronary graft expected late 2025.
- **Cost Efficiency**: $38M 2026 savings from workforce reduction and expense cuts.
- **Military Expansion**: 190 military/Veterans Affairs facilities targeted, with bulk purchase discussions.

**【CEO Summary Section】**
- **Symvess Commercial Momentum**: 82 civilian hospitals (up from 5) and 35 military facilities now eligible to purchase Symvess, with $0.3 million in July sales exceeding H1 revenue. First military sale achieved in Q2, with reorder activity.
- **VAC Expansion**: 13 organizations approved, 40 VAC reviews ongoing. Price reduction to $24,250 streamlined approvals, maintaining margins.
- **Pipeline Progress**: ATEV Phase III trial (V007) shows 8-month access usability vs. 4.5 months for fistulas in high-risk patients. V012 trial (100/150 enrolled) targeting women; interim analysis in April 2026 for BLA filing.
- **Coronary Graft Update**: Primate study paper accepted; IND filing expected late 2025, with trials in 2026.

**【CFO Financial Commentary】**
- **Q2 2025 Results**: $0.3M revenue (Symvess $0.1M, research $0.2M), net loss $37.7M (vs. $56.7M in 2024). 2025/2026 cost savings $3.8M/$38M from workforce reduction (30 employees) and expense cuts.
- **Cash Position**: $88.4M as of June 30, 2025. 2025H1 cash used $6.9M, offset by $46.7M equity raise.

**【Q&A Highlights】**
- **Pricing Strategy**: $24,250 price point standard, with annual reviews. VAC approval time reduced to 6-9 months post-price cut.
- **CMS NTAP Denial**: Minimal impact (4.3% Medicare coverage); private payer discussions ongoing, supported by budget impact model.
- **Military Channel Growth**: Targeting 190 military/Veterans Affairs facilities. Procurement process for bulk purchases underway.
- **Clinical Trial Enrollment**: Aiming for 150 V012 patients by year-end; interim analysis in April 2026 could accelerate BLA filing.
- **Real-World Evidence**: FDA registry of 100 trauma patients to launch, complementing hospital-reported success stories.

Humacyte, Inc. (HUMA) Q2 2025 Earnings Call Transcript

- **Symvess Commercial Momentum**: 45 hospitals in VAC process, 5 approvals secured; 25% of U.S. Level 1 trauma centers engaged. 
- **Cost Efficiency**: $13.8M annual savings from workforce reduction and expense cuts. 
- **Pipeline Progress**: 
  - Small-diameter ATEV IND filing planned for 2025. 
  - V012 dialysis trial 56% enrolled; interim analysis Q2 2026. 
  - BioVascular Pancreas program advancing with primate implants. 
- **Financial Strength**: $113.2M cash runway; Q1 2025 net income $39.1M (vs. $31.9M loss YoY). 
- **Reimbursement Outlook**: NTAP ruling response due mid-June; potential CMS adoption Q4 2025. 


**【CEO Summary Section】**
- **Symvess Commercial Launch Progress**: 45 Level 1 trauma centers have initiated VAC approval process, with 5 approvals secured. First commercial shipments made to 3 trauma centers in Q1 2025. 
- **Market Traction**: 25% of U.S. Level 1 trauma centers engaged in evaluation; military treatment facilities express interest. 
- **Cost Control**: $13.8M annualized savings from workforce reduction (31 employees) and operating expense cuts. 
- **Pipeline Updates**: 
  - Small-diameter ATEV IND filing planned for 2025; first-in-human trial in coronary bypass surgery. 
  - V012 Phase 3 dialysis trial enrolls 84/150 patients; interim analysis scheduled for Q2 2026. 
  - BioVascular Pancreas program advancing with primate implants and lab experiments. 

**【CFO Financial Commentary】**
- **Q1 2025 Financials**: 
  - Total Revenue: $517K (Symvess: $147K; research collaboration: $370K) 
  - Net Income: $39.1M (vs. $31.9M loss in Q1 2024) 
  - Cash Position: $113.2M (post $46.7M March 2025 equity offering) 
  - R&D Expenses: $15.4M (down 27% YoY due to inventory capitalization) 
  - G&A Expenses: $8.1M (up 53% YoY due to commercial launch costs) 
- **Cash Runway**: Extended through cost reductions and March 2025 financing. 

**【Q&A Key Takeaways】**
1. **Symvess Adoption**: 
   - 3 initial commercial sites completed first implants; VAC approval conversion rate >80%. 
   - Economic model shows Symvess reduces total treatment cost by $10K+ per patient. 
   - Military hospitals expect to order via ECAT listing; no additional VAC process required. 
2. **Dialysis Pipeline**: 
   - V012 trial targeting women and diabetic patients (50%+ of dialysis market). 
   - Fresenius partnership leverages shared interest in reducing catheter-dependent patients. 
3. **Sales Force Strategy**: 
   - Current 15-person team sufficient for 2025 targets; expansion contingent on VAC approvals. 
   - 40% of VAC submissions from hospitals with no prior clinical trial experience. 
4. **Reimbursement Progress**: 
   - NTAP proposed ruling response due mid-June; potential CMS adoption in Q4 2025. 
   - Private payor coverage discussions ongoing. 


Humacyte (HUMA)-13 May 25-2025 Q1 Earnings call transcript

- **Symvess Commercial Success**: 3 hospitals approved, first shipments made within 16 days; NTAP reimbursement pending for 2025.
- **Cost Efficiency**: Symvess reduces per-patient costs by 20%+ vs. alternatives, supported by published budget impact model.
- **Pipeline Momentum**: ATEV for dialysis on track for H2 2026 BLA; small-diameter ATEV IND filing planned; BVP shows long-term insulin production in primates.
- **Financial Strength**: $95.3M cash balance post-$46.6M raise; 2025 sales guidance $7-13M, 70%+ in H2.


**【CEO Opening Remarks】**
- FDA granted full approval for Symvess in December 2024, marking a 20-year R&D milestone for treating extremity vascular trauma.
- 34 hospitals have initiated VAC approval processes, with 3 approvals secured and first commercial shipments made to Level 1 trauma centers within 16 days of inventory availability.
- Budget impact model shows Symvess reduces per-patient costs compared to synthetic grafts, cryopreserved allografts, and xenografts.
- Submitted NTAP application to CMS for additional reimbursement starting October 2025.
- New U.S. patent issued for Symvess manufacturing system, extending protection to 2040.

**【CFO Financial Review】**
- Q4 2024: No revenue; R&D expenses $20.7M (down 10% QoQ due to manufacturing timing), G&A $7.4M. Net loss $20.9M (vs. $39.2M QoQ) due to contingent earn-out remeasurement.
- FY 2024: R&D $88.6M (+16% YoY), G&A $25.8M (+10% YoY). Net loss $148.7M (vs. $110.8M YoY). Cash balance $95.3M as of Dec 31, 2024, with $46.6M raised post-period.

**【CEO Pipeline Update】**
- ATEV for dialysis: V007 Phase III met endpoints, showing superior patency in women, obese, and diabetic patients. V012 Phase III enrolling 76/80 female patients for interim analysis.
- Small-diameter ATEV for CABG: IND filing planned based on preclinical primate study showing patency, recellularization, and remodeling.
- Biovascular pancreas (BVP): Primates show long-term insulin production and survival; optimizing design for therapeutic impact.

**【Q&A Highlights】**
- **Market Adoption**: 3 hospitals approved Symvess within 3-6 months, driven by surgeon champions and compassionate use cases. Expect 2025 sales between $7-13M, with 70%+ in H2.
- **Clinical Trials**: V012 interim analysis on 80 female patients expected Q2 2025; supplemental BLA for dialysis access planned H2 2026.
- **Manufacturing Costs**: Smaller-diameter ATEV for CABG expected to have lower production costs than trauma grafts.
- **PAD Program**: Phase III design underway, timing dependent on cash position post-$46.6M equity raise.
- **FDA Review**: Supplemental BLA for dialysis likely to take <12 months, seeking priority review.


HUMA

HUMA fundamentals

Earnings Call

You can ask Aime